The problems of developing new antibiotics is that it is a never ending technology race.
New drugs are targeted at those areas where there are a sufficient number of patients to (eventually) pay for the cost of development. Only when existing drugs no longer are effective (due to resistant strains of infectious agents), will doctors prescribe newer more expensive drugs. Some antibiotics and antivirals will end up being niche drugs, for those with special needs.
These situations can lead to an inability to recover developmental costs before the patent expires
This means, the developers are tempted to keep the prices very high. Unfortunately, this discourages use and doctors refuse to prescribe the drug. Some drug companies launch a massive advertising campaign to pump up sales before the patents can expire. This encourages over use, which detracts from the useful life of the drugs.
Too many drug companies therefore, have started shying away from expensive development on a drug that will never make money for them.
ScienceMag features a story on a UK Government proposal for a global government administered program that would guarantee drug developers a profit, rather than extending patent length.
The new report full text pdf here estimates that the world needs 15 new antibiotics per decade, at least four of which should have new mechanisms of action to target the most harmful pathogens.
Toward that end the UK plan would create a $2 billion "global innovation fund," bankrolled by pharmaceutical companies to kick-start development of promising drug studies.
To incentivize drug development without encouraging overuse, the report promotes an idea gaining popularity in antibiotics: "de-linking" a drugmaker's profits from the drug's sales. Such strategies aim to give companies assurance that they will make money if they bring valuable new antibiotics to market, regardless of the number of pills prescribed right away.
They suggest that a comprehensive package of interventions could cost as little 16 billion USD and no more than 37 billion USD over the course of 10 years and would be sufficient to radically overhaul the antibiotics pipeline.
Presumably such a program would come with some requirement to keep prices low, or require them to license others to manufacture the drugs at reasonable royalty rates well before the patents expire.
(Score: 2) by Tork on Friday May 15 2015, @05:10PM
🏳️🌈 Proud Ally 🏳️🌈
(Score: 1, Insightful) by Anonymous Coward on Friday May 15 2015, @09:20PM
Death panels, decided by the contents of your wallet. Basically, supporters of for-profit healthcare are supporters of executing the poor.